Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 3 |
| List of Tables | 8 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Accelerating Drugs to Market - Overview | 10 | 10 |
| Drug Development Process | 12 | 1 |
| Early Stage Drug Discovery | 12 | 1 |
| Clinical Development Time and Protocol Amendments | 13 | 1 |
| Phase I | 14 | 1 |
| Phase II | 14 | 1 |
| Phase III | 14 | 1 |
| Registration | 14 | 1 |
| Phase IV | 14 | 1 |
| Need to Accelerate the Drug Development Process | 15 | 1 |
| Strict Regime in Regulations of Drug Approvals | 15 | 1 |
| Declining Returns on R&D Investment | 16 | 1 |
| Low R&D Productivity | 17 | 1 |
| Misconceptions of Accelerated Drug Development | 17 | 1 |
| Completeness of the Drug Development Process | 17 | 1 |
| Cost of Accelerated Drug Development | 17 | 1 |
| Quality of Study in Accelerated Drug Development | 17 | 1 |
| Causes of Delay in Drug Development | 18 | 1 |
| Delay during the Nonclinical Stage of Drug Development | 18 | 1 |
| Interruption of Drug Supplies | 18 | 1 |
| Objectives of Nonclinical Studies Do Not Match with Clinical Goals | 18 | 1 |
| Delay During the Clinical Stage of Drug Development | 18 | 1 |
| Inability to Resolve Issues Due to Lack of Internal Processes | 18 | 1 |
| Issues with Patient Recruitment and Retention | 18 | 1 |
| Issues with Manufacturing | 19 | 1 |
| Issues with Ethics Committee | 19 | 1 |
| Accelerating Drugs Through the Lead Generation Phase | 20 | 18 |
| Process of Lead Generation | 20 | 1 |
| Pre-Discovery | 20 | 1 |
| Target Identification | 21 | 1 |
| Target Validation | 21 | 1 |
| Lead Identification | 22 | 1 |
| Early Safety Tests | 22 | 1 |
| Lead Optimization | 23 | 1 |
| Traditional Strategies of Lead Generation | 24 | 1 |
| High Throughput Screening | 24 | 1 |
| In Vitro Studies of Drug Absorption | 25 | 1 |
| Extrapolation of In Vitro Absorption Data | 25 | 1 |
| In Vitro Studies of Protein Binding | 25 | 1 |
| In Vitro/In Vivo Protein Binding | 25 | 1 |
| Plasma and Tissue Protein Binding | 26 | 1 |
| Fragment-Based Lead Discovery | 26 | 1 |
| Advantages of Fragment-Based Drug Design over High Throughput Screening | 26 | 1 |
| Antisense Technology | 27 | 1 |
| Iterative Focused Screening | 28 | 1 |
| Emerging Strategies of Lead Generation | 28 | 1 |
| Improving High Throughput Screening | 28 | 1 |
| Improving In Vitro Assays for HTS | 29 | 1 |
| Whole Animal Imaging and Microscopy | 29 | 1 |
| Computerized Combinatorial Chemistry and 3D Molecular Modeling | 30 | 1 |
| Quantitative Structure Activity Relationship | 30 | 1 |
| Computer Aided Drug Design | 30 | 1 |
| Computer Automated Structure Evaluation | 30 | 1 |
| Molecular Modeling | 30 | 1 |
| Service Providers | 31 | 1 |
| Case Studies | 32 | 1 |
| Molecular Bioimaging | 32 | 1 |
| Case Study | 32 | 1 |
| Omics-Technology and Bioinformatics | 33 | 1 |
| Service Providers | 34 | 1 |
| Case Study | 35 | 1 |
| Outsourcing of Lead Generation | 36 | 1 |
| Case Study | 37 | 1 |
| Accelerating Drugs Through the Preclinical Stage | 38 | 8 |
| Preclinical Studies - An Overview | 38 | 1 |
| Preclinical Study Design and Planning | 38 | 1 |
| Preclinical Study - Strategic Planning | 38 | 1 |
| Key Considerations During Preclinical Study Design | 38 | 1 |
| Establishment of Rationale | 38 | 1 |
| Identification and Selection of a Clinical Indication | 38 | 1 |
| Selection of an Appropriate Species | 39 | 1 |
| Pharmacodynamic and Pharmacokinetic Parameters | 39 | 1 |
| Characterization of Toxicities | 39 | 1 |
| Strategies and Models to Accelerate the Transition from Preclinical Phase to Clinical Phase I | 39 | 1 |
| In Vitro ADMET Screening Models | 40 | 1 |
| In Vivo ADMET Screening Models | 40 | 1 |
| Vertebrate Models | 40 | 1 |
| Invertebrate Models | 41 | 1 |
| In Silico ADMET Screening Models | 41 | 1 |
| Protein Modeling | 41 | 1 |
| Accelerating Drugs to Market through Effective Documentation in the Preclinical Phase | 41 | 1 |
| Recent Technology Developments | 42 | 1 |
| Biomarkers | 42 | 1 |
| Nanotechnology | 42 | 1 |
| In Vivo Imaging | 43 | 1 |
| Accelerating Drugs to Market - Preclinical Models: Case Studies | 43 | 1 |
| Apredica s Customized In Vitro ADMET Screening Assays | 43 | 1 |
| AVEO Pharmaceuticals Breakthrough with Transgenic Mouse Model for Human Breast Cancer | 44 | 1 |
| Preclinical Models of Hepatocellular Carcinoma and Biomarker Strategy by Pfizer | 44 | 1 |
| Simulation Modeling to Treat Spinal Cord Injuries by Novartis | 45 | 1 |
| Accelerating Drug Transition in Phase I Studies | 46 | 7 |
| Phase I Clinical Studies - An overview | 46 | 1 |
| Phase I Study Design and Planning | 46 | 1 |
| Standard Design | 46 | 1 |
| Strategies and Models to Accelerate Transition from Phase I to Phase II | 46 | 1 |
| Site Selection and Management | 46 | 1 |
| Site Initiation Process | 47 | 1 |
| Site Selection and Qualification | 47 | 1 |
| Contract and Budget Negotiation | 48 | 1 |
| Regulatory Submission and Approval | 48 | 1 |
| Strategies to Minimize Site Initiation Delays | 48 | 1 |
| Translation of Study Material | 48 | 1 |
| Contracts by Function | 48 | 1 |
| Legal and Ethical Plan | 49 | 1 |
| Proper Project Management Approach | 49 | 1 |
| Role of the Site Management Organization in Decreasing Timelines | 49 | 1 |
| Effective Patient Recruitment | 49 | 1 |
| Support and Guidance | 49 | 1 |
| Partnership with Investigators | 50 | 1 |
| Timely Ethics Committee Management | 50 | 1 |
| Optimizing Clinical Trial Supply through a Clinical Trial Management System | 50 | 1 |
| Patient Recruitment Strategies | 51 | 2 |
| Accelerating Drug Transition in Phase II Studies | 53 | 3 |
| Phase II Clinical Studies - An Overview | 53 | 1 |
| Phase II Study Design and Planning | 53 | 1 |
| Strategies and Models to Accelerate Transition from Phase II to Phase III | 53 | 1 |
| Selection of Primary Endpoint | 53 | 1 |
| Randomization of Phase II Trials | 53 | 1 |
| Use of Biomarkers | 54 | 1 |
| Statistical Designs in Phase II Trials | 54 | 1 |
| Increasing Patient Recruitment through the Use of Social Media | 54 | 1 |
| Seamless Phase II/III Designs | 55 | 1 |
| Accelerating Drug Transition in Phase III Studies | 56 | 2 |
| Trends in Drug Transition from Phase III to NDA Filing | 56 | 1 |
| Issues and Challenges in Drug Transition | 56 | 1 |
| Strategies and Models to Accelerate Transition from Phase III to NDA Filing | 56 | 1 |
| Adaptive Trial Designs | 56 | 1 |
| Recruitment and Retention of Patients in Phase III Clinical Trials | 57 | 1 |
| Accelerating Drugs to Market - Appendix | 58 | 6 |
| Market Definitions | 58 | 1 |
| Abbreviations | 58 | 1 |
| Bibliography | 59 | 3 |
| Research Methodology | 62 | 2 |
| Coverage | 62 | 1 |
| Secondary Research | 62 | 1 |
| Primary Research | 62 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 63 | 1 |